March 17, 2020 / 5:43 PM / 19 days ago

BRIEF-OSE Amends Global Licensing Option Agreement For OSE-127 With Servier

March 17 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:

* WITH SERVIER TODAY ANNOUNCED EXECUTION OF AN AMENDMENT TO TWO-STEP GLOBAL LICENSING OPTION AGREEMENT FOR EXCLUSIVE GLOBAL RIGHTS TO INTERLEUKIN-7 RECEPTOR (IL-7R) ANTAGONIST OSE-127

* AMENDMENT MODIFIES THE PROVISIONS REGARDING THE OPTION EXERCISE MODALITIES AND ASSOCIATED FINANCIAL CONDITIONS

* BASED ON POSITIVE PHASE 1 RESULTS WITH OSE-127, TWO INDEPENDENT PHASE 2 CLINICAL STUDIES ARE EXPECTED TO START IN 2020

* OSE IS ELIGIBLE TO RECEIVE UP TO A TOTAL OF €272 MILLION IN DEVELOPMENT, REGULATORY AND SALES MILESTONES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below